BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22207052)

  • 1. The combination of surgery and imatinib in GIST: a reality for localized tumors at high risk, an open issue for metastatic ones.
    Gronchi A; Raut CP
    Ann Surg Oncol; 2012 Apr; 19(4):1051-5. PubMed ID: 22207052
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
    Wang D; Zhang Q; Blanke CD; Demetri GD; Heinrich MC; Watson JC; Hoffman JP; Okuno S; Kane JM; von Mehren M; Eisenberg BL
    Ann Surg Oncol; 2012 Apr; 19(4):1074-80. PubMed ID: 22203182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
    Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical resection in metastatic gastrointestinal stromal tumors.
    Choi EA; Feig BW
    Curr Oncol Rep; 2007 Jul; 9(4):303-8. PubMed ID: 17588355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Personalized therapy: prognostic factors in gastrointestinal stromal tumor (GIST).
    Dematteo RP
    J Gastrointest Surg; 2012 Sep; 16(9):1645-7. PubMed ID: 22752549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emergence of secondary resistance to imatinib in recurrent gastric GIST.
    Jayanthi NV
    J Gastrointest Surg; 2010 Dec; 14(12):2018-9; author reply 2020. PubMed ID: 20714935
    [No Abstract]   [Full Text] [Related]  

  • 7. [Consensus on the medical treatment of gastrointestinal stromal tumors].
    Zhonghua Zhong Liu Za Zhi; 2007 Nov; 29(11):875-7. PubMed ID: 18396652
    [No Abstract]   [Full Text] [Related]  

  • 8. Combined Therapy of Gastrointestinal Stromal Tumors.
    Rutkowski P; Hompes D
    Surg Oncol Clin N Am; 2016 Oct; 25(4):735-59. PubMed ID: 27591496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal stromal tumors: current management.
    Pisters PW; Patel SR
    J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib: as adjuvant therapy for gastrointestinal stromal tumor†: profile report.
    Sanford M; Scott LJ
    BioDrugs; 2011 Jun; 25(3):191-2. PubMed ID: 21627342
    [No Abstract]   [Full Text] [Related]  

  • 11. Gastrointestinal stromal tumor (GIST) -- single center experience of prolonged treatment with imatinib.
    Schindler CG; Armbrust T; Gunawan B; Langer C; Füzesi L; Ramadori G
    Z Gastroenterol; 2005 Mar; 43(3):267-73. PubMed ID: 15765299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate.
    Warakaulle DR; Gleeson F
    AJR Am J Roentgenol; 2006 Feb; 186(2):510-5. PubMed ID: 16423961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal stromal tumor (GIST) and imatinib.
    Kubota T
    Int J Clin Oncol; 2006 Jun; 11(3):184-9. PubMed ID: 16850124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.
    Gronchi A; Fiore M; Miselli F; Lagonigro MS; Coco P; Messina A; Pilotti S; Casali PG
    Ann Surg; 2007 Mar; 245(3):341-6. PubMed ID: 17435538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
    Lai IR; Hu RH; Chang KJ
    Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.
    Mazzeo F; Duck L; Joosens E; Dirix L; Focan C; Forget F; De Geest S; Muermans K; VAN Lierde MA; Macdonald K; Abraham I; De Grève J
    Anticancer Res; 2011 Apr; 31(4):1407-9. PubMed ID: 21508393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib and gastrointestinal stromal tumor (GIST): a selective targeted therapy.
    Fernández A; Aparicio J
    Rev Esp Enferm Dig; 2004 Oct; 96(10):723-6; 727-9. PubMed ID: 15537379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [GIST: our experience].
    Rossi MT; Fasano G; Morlino A; Scutari F
    G Chir; 2009; 30(1-2):41-5. PubMed ID: 19272232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controversies in the surgical management of GIST in the era of imatinib.
    Raut CP; Bertagnolli MM
    Oncology (Williston Park); 2009 Jan; 23(1):69, 74-6. PubMed ID: 19283924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.